Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Colchicine for prevention of major adverse cardiac events after PCI in STEMI
IRCT20230801059005N1Phase 3Completed
- Sponsor
- Shiraz University of Medical Sciences
- Start
- Sep 2023
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of colchicine in myocardial infarction (MI) (2 arms), sponsored by Shiraz University of Medical Sciences. Primary endpoint: major adverse cardiac events. Started Sep 2023; status: completed.
02
Drugs
colchicine
03
Conditions
myocardial infarction (MI)
Beyond the preview
Go deeper on IRCT20230801059005N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20230801059005N1.